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1 – Summary 
The aggressive behavior of tumor metastasis and the lack of effective treatments are 
conditions that warrant the study of basic mechanisms of metastasis. The brain is one of the 
sites where breast cancer often forms metastasis. A model of spontaneous breast cancer 
brain metastasis has been previously generated in the laboratory and a gene expression 
profile has been determined. From the microarray analysis a list of genes with potential 
clinical relevance for breast cancer metastasis to the brain has been identified, based on 
their correlation with reduced BMFS (Brain Metastasis-Free Survival) parameter as 
determined by bioinformatic analysis of breast cancer gene expression data bases. 
The aim of this project was to functionally characterize a subset of these up-regulated genes 
previously identified in genome-wide screening to mediate spontaneous experimental breast 
cancer metastasis to the brain, in order to understand the biological implications of these 
selected genes. Here we provide evidence that the Cx31 protein promotes cell proliferation, 
resistance to apoptosis and stem cell self-renewal potential. In addition, the EDN1 peptide 
provides a pro-migratory pattern, promoting effects of resistance to apoptosis and stem cell 
self-renewal potential. Further findings are a pro-migratory activity of CTGF and a promoting 
stem cell self-renewal potential of IL1R2. 
In short, results obtained from this project are expected to contribute to a better 
understanding of the mechanism of breast cancer metastasis to the brain and to identify 
novel therapeutic approaches. 
 
 
2 – Introduction 
Breast cancer is the most common type of cancer occurring in women, representing around 
10% of all cancer incidences worldwide. Advanced therapeutic approaches as hormonal 
therapy, chemotherapy and targeted therapies continuously improved progression-free and 
overall survival of breast cancer patients over the past 20 years. Currently, the limiting factor 
in breast cancer survival is, as a matter of fact, the formation of distant metastasis to vital 
organs, and the lack of effective treatments to prevent or cure them. 
 
Preferred primary metastatic sites for breast cancer are lung, bone and liver. Traditionally 
breast cancer metastasis to the brain occurred in less than 20% of the patients and was 
often associated with an advanced stage of the disease. Nowadays, however, the number of 
breast cancer patients experiencing brain metastasis is increasing due to their extended 
survival thanks the improved therapeutic management of the primary lesions. In fact it 
appears that adjuvant therapy effectively controls disease progression in the periphery (i.e. 
metastasis to lung, bone and liver), but fail to impinge on metastasis formation in the brain. 
This is in part due to the limited ability of chemotherapy and targeted drugs to pass the blood 
brain barrier. 
 
Today brain metastasis occurs in approximately 30% of breast cancer patients and causes 
death within 6 months from the diagnosis. Autopsy studies suggest that its incidence is likely 
to be underestimated due to asymptomatic lesions in many cases. It is likely that the 
incidence of breast cancer brain metastasis will rise continuously, because on improved 
overall survival and lack of effective therapy against brain metastasis (Ref. 1). Thus there is 
an urgent need to better understand mechanisms governing breast cancer brain metastasis 
formation. 
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Metastasis, is defined as the spread and growth of cancer cells from a primary tumor site to 
distant secondary organs as a multi-step process. At a phenomenological level, cancer cells 
have to perform several discrete steps in order to metastasize. They include: (1) loss of cell-
cell adhesion and gain of cell-matrix adhesion and local invasion, (2) intravasation, (3) 
intravasation and survival in the circulation, (4) extravasation, (5) formation of micro-
metastasis, and (6) growth at the distant site. The current paradigm defines metastasis as a 
process driving the selection of cells with advantageous traits that allow them to overcome 
the diverse environmental defense mechanisms preventing growth of cells in tissues different 
from the ones of origin. Metastasis is associated with important changes in gene expression 
(Ref. 2). Our current understanding of metastasis formation indicates that the emergence of 
metastatic cells might be driven by the selection of a limited set of stochastically accumulated 
combinatorial functions necessary for the growth and survival of the tumor cells at the 
primary site, rather than the de novo selection of rare cells overexpressing a limited number 
of ‘metastasis-specific’ genes (Ref. 3). This situation is reminiscent of infection organisms 
becoming highly pathogenic through the acquisition of only a few ‘virulence’ genes. 
Malignant tumors often metastasize following an organ-specific pattern, defined by 
metastasis organ tropism. For example, bone metastases preferentially originate from lung, 
prostate or breast carcinoma. This relation between a certain type of cancer and a particular 
organ location for its metastatic colonization suggests the need for a tumor cell to interact 
with, adapt to and survive within a specific “foreign” tissue microenvironment. Paget first 
evoked this notion on 1889 in his “seed and soil” theory. 
In case of breast carcinoma, metastases occur mainly in lung, bone, liver and brain. Breast 
cancer is the third most common tumor metastasizing to brain after lung carcinoma and 
melanoma. However, it is the most common one due to the higher incidence of breast 
cancer. The mechanisms mediating breast cancer brain metastases remain still largely 
unknown. 
The group of Dr. Massagué recently reported the identification of genes mediating breast 
cancer metastasis to the bone, lung and brain, which include the epidermal growth factor 
receptor (EGFR) ligand epiregulin, COX2, MMP 1 and MMP2 (Ref. 4). 
In order to identify additional genes mediating breast cancer metastasis to the brain, the host 
laboratory has developed the first orthotopic model of breast cancer metastasis to the brain 
in immunocompetent mice using the 4T1 breast cancer model in BALB/c mice. Through two 
cycles of in vivo selection this lab has generated 4T1-derivative lines (4T1-BM2) that form 
brain metastasis with 100% penetrance. Thereupon a list of genes associated with brain 
metastasis was compiled through gene expression profiling of brain metastatic and non- 
brain metastatic cells and bioinformatic analysis of gene expression profiles in human breast 
cancer patients datasets. 30% of the identified genes were identical or related to those 
reported by Massagué’s group. Many genes related to inflammation and cell-cell 
communication were identified. A small set of up-regulated genes was selected based on the 
association of their human othologues with reduced brain metastasis-free survival in human 
patients, for further detailed in vitro and vivo characterization. In this project, we investigated 
five genes, which have been implicated in mediating brain metastasis in the 4T1 model, but 
their mechanism of action has not been elucidated yet.  
 
One of them is the gap junction protein beta 3 (GJB3 also known as Connexin 31 - Cx31), a 
member of the connexin gene family. As specialized cell-cell contact molecules, their role is 
to mediate the passive diffusion of molecules such as nutrients, small metabolites (e.g. 
glucose), ions (K+, Ca2+) and second messengers (IP3, cAMP and cGMP) from one cell to 
another (Ref. 5). To date, little is known on the role of connexins in cancer. Using connexin-
transfected HeLa cells, Graeber and Hülser reported that forced expression of connexins 
Cx31, Cx40, or Cx43 promoted invasion of tumor cells in an in vitro chicken heart model 
(Ref. 6). 
 
Another analyzed molecule is the endothelin 1 peptide (EDN1), a member of the endothelin 
family, consisting of potent vasoconstrictor peptides with three endogenous isoforms and two 
distinct receptors (Ref. 7). EDN1 has been proposed to function as an auto- and paracrine 
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growth factor for certain tumor cells, especially for ovarian cancer cells (Ref. 8-9). Targeting 
endothelin A receptor and HER2 in HER2-overexpressing breast cancer cells reduced 
proliferation and invasion (Ref. 10). 
 
A third gene of interest is connective tissue growth factor (CTGF). CTGF belongs to the CCN 
family of matricellular proteins (the CCN stands for CTGF, Cystein rich protein (Cyr61), and 
Nephroblastoma overexpressed gene, the first three identified members of the family) (Ref. 
11), which biological properties that include the stimulation of cellular proliferation, migration, 
adhesion, extracellular matrix formation, as well as the regulation of angiogenesis and 
tumorgenesis (Ref. 12). Hence, CTGF plays multiple roles in various cancer types. In breast 
cancer cells CTGF overexpression has been linked to increased tumor size and lymph node 
metastasis (Ref. 13, 14), as well as to usual resistance to apoptotic stress (Ref. 12) and 
critical involvement in the formation of osteolytic bone metastasis (Ref. 15, 16).  
 
A forth gene of interest encodes for the laminin gamma 2 chain (LAMC2), part of the laminin 
family of extracellular matrix glycoproteins, implicated in a wide variety of biological 
processes including cell adhesion, differentiation, migration, signaling, neurite outgrowth and 
metastasis (Ref. 17). Today's findings on the LAMC2 expression show a correlation with 
hematogenous spread of cancer cells in contrast to lymphatic metastasis in bladder cancer 
(Ref. 18) and a coordinated promigratory activity with Membrane type 1 metalloprotease at 
the invasive front of colorectal carcinomas (Ref. 19).  
 
A fifth gene of interest is the interleukin 1 receptor type II (IL1R2) that belongs to the 
interleukin 1 receptor family. IL1R2 has been proposed to act as a decoy receptor, inhibiting 
the activity of IL1A, IL1B, thereby reducing IL1R1 signaling (Ref. 20). IL1R2 plays a 
physiological role in inflammation, proliferation and apoptosis (Ref. 20). Rückert et al, 
reported for the first time an upregulation of IL1R2 in pancreatic cancer (Ref. 21). They 
proposed that IL1R2 protects pancreatic cancer cells from apoptosis, whereas the 
microenvironment might benefit from the angiogenic and proliferative properties of IL1 
secreted by pancreatic cancer cells as well (Ref. 22). 
 
 
3 – Aim of the study 
Our objective was to test, whether the genes GJB3, EDN1, CTGF, LAMC2, IL1R2, among 
those identified in a gene expression analysis screen in non-brain metastatic (4T1-T2) vs. 
brain metastatic (4T1-BM2) cells, were functionally implicated in influencing the 
aggressiveness of breast cancer cells toward the formation of brain metastasis. 
 
 
4 – Experimental approach 
The proposed experiments are performed in vitro using 4T1-derived cell lines. 
 
Part 1: Suppression of expression of selected genes by RNAi approach (gene 
silencing) 
To knock-down genes of interest we used a gene silencing approach based on RNA 
interference (RNAi). Short hairpin RNA’s are transduced into target cells (i.e metastatic 4T1 
variants). Among genes of interest correlating with the metastatic phenotype five were 
previously silenced in the host laboratory (Cx31, CTGF, EDN1, IL1R2, LAMC2), by lentivirus-
mediate gene transfer of short hairpins RNA (shRNA). 
Plasmid containing the shRNA of interest were purchased commercially (Sigma) and used to 
generate a lenti virus by cotransfection in HEK 293 cells. Supernatants were then used to 
infect 4T1-BM2 cells. The validity of gene silencing was then determined by measuring 
mRNA level by quantitative real time qRT-PCR and by detecting the protein expression by 
Western blot analysis. 3-5 different shRNA constructs were used for each gene to be 
silenced. This part of the study was performed before my arrival in the lab. 
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Part 2: Analysis of the biological effect of gene silencing 
The effect of gene silencing on 4T1-BM2 cell activities was monitored in cell culture and 
functional experiments. We analyzed 4T1 parental cells, 4T1-BM2 cells and 4T1-BM2 cells 
silenced for the specific genes (4T1-Bm2 Cx31kd, T1-BM2 CTGFkd, 4T1-Bm2 EDN1kd, 4T1-
BM2 IL1R2kd, 4T1-BM2 LAMC2kd) in assays testing properties potentially associated with 
metastasis: proliferation, survival, migration/invasion and “stem cell” activity. The following in 
vitro assays were used: 
 
4.1. Proliferation assay 
Cells were seeded in 96 well micro-titer plates at low density (1000 cells/well) and their 
growth was monitored daily for up to 5 days by crystal violet staining followed by elution and 
densitometry (O.D.) analysis. We used one 96 well plates for each time point (t=0 hours, 
t=24 hours, t=48 hours, t=72 hours, t=96 hours). The cells were allowed to attach for 18 
hours before the experiment was started. Each cell line was seeded in 8 wells per plate in 
200 µl of medium (500 ml DMEM, 10% FCS, 1% penicillin/streptomycin solution, 1% non-
essential amino acids, NEAA) per well. Once the experiment started, plates were placed into 
a humidified cell culture incubator at 37°C and 5% CO2. The procedure in terms of the 
reading points was to control microscopically the aspect of the cell attachment and the 
exclusion of contamination before the medium was aspirated. Afterwards the cells were 
washed once with phosphate-buffered saline (PBS), fixed and stained for 20 minutes at room 
temperature with a 160 µl of a solution containing 4 % Paraformaldehyde and 2 % crystal 
violet per well. The plates were rinsed and air-dried overnight. Finally, crystal violet was 
resolubilized using 100 µl destainer solution (1% acetic acid, 50% ethanol, 50% deionized 
water) per well to quantify absorbance at 595nm wavelenght. 
 
4.2. Resistance to hypoxia assay 
Cells were cultivated in 12 well plates at high density (100’000 cells/well) under standard (i.e. 
20% oxygen) and hypoxic (0.1% oxygen) conditions. We used 4 wells per plate for each cell 
line in each oxygen condition with 1 ml of DMEM medium per well. The cells were allowed to 
attach for 18 hours before the experiment was started. Once the experiment started all plates 
were placed into the incubator at 37°C, 5% CO2 and the appropriated oxygenic condition 
during 24 hours. Finally, the cells were controlled microscopically before the medium was 
aspirated. After washing once with PBS, splitting the cell adhesion with trypsin during 4 
minutes in the incubator, neutralizing the protease activity by adding DMEM medium and 
centrifuging, the number of cells per unit volume of a suspension was determined by using a 
counting chamber (Neubauer hemocytometer). Dead cells and debris were excluded by 
trypan blue exclusion staining. 
 
4.3. Migration and invasion assays.  
To test migration capability, cells were seeded in 6 well plates at high density (500’000 cells 
in 2 ml DMEM medium/well) to grow till confluence. A sharp a wound was applied in the 
middle of the well with a 1000 µl micropipette tip. Wound healing was monitored till its 
closure during 24 hours by time lapse imaging using a Leica DMI6000B microscope 
equipped with a CO2/Temp- conditioned incubator as documented by a 24 hours time-lapse 
movie. Duplicate wells were used per condition. 
 
4.4. Mammosphere formation assay  
Cells were seeded on a non-adhesive surface in a 96 well micro-titer plate at low density 
(5’000 cells/well). We used MEGM (mammary epithelial growth medium) to assure 
anchorage independent growth. Hence, each cell line obtained 10 wells per plate and 100 µl 
of MEGM. Every third day, the cells received 100 µl of culture medium MEGM over a period 
of 10 days. Finally, the number of formed spheroids and their sizes was assessed on 
microscopically collected/documented images.  
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4.5. Statistical analysis  
Statistical validation of the collected data was determined by using the bilateral Student’s t-
test. Results were then ranked as * for a t test value <0,05, ** for a t test value <0,005, *** for 
a t test value <0,001, or NS, non-significant, for a t test value >0,05. 
 
 
5 – Results 
 
5.1. – 4T1-BM2 Cx31kd cells have a reduced proliferative capacity in an in vitro 
proliferation assay compared to the parental and 4T1-BM2 cell lines, as well as the 
other cell lines with selected gene-silenced.  
To determine whether one of the selected genes (Cx31, CTGF, EDN1, IL1R2, LAMC2) 
silenced in the 4T1-BM2 cell line play a significant role in breast cancer cell proliferation, we 
examined the proliferation rate of each cell line with the silenced genes and compared it with 
two control cell lines (4T1-T2 parental and 4T1-BM2 cells) in an in vitro proliferation assay. 
We did a time course experiment and we first analyzed the raw values obtained at the time of 
72 hours. Later time points were avoided due to cell confluence. We performed a 
normalization of the data obtained (Figure 1), by dividing the values of the different time 
points by the value at 24 hours, to illustrate the cell growth rate. We observed a significant 
reduction in cell growth rate of the 4T1-BM2 Cx31kd cell line related to all the other gene-
silenced cell lines (19.7 ± 14.0 %, p < 0.006; at 72 hours), as well as the controls (20.9 ± 13.8 
%, p < 0.005; at 72 hours). 	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Figure 1. Cell proliferation. Proliferation rate 
of each cell line with the silenced genes, 
compared to the two control cell lines (4T1-T2 
parental and 4T1-BM2 cells) at 72 hours. (A) 
reduced proliferation in 4T1-BM2 Cx31kd cells 
(to 4T1-T2, **, P<0.0015, to 4T1-BM2, **, 
P<0.005, students t test). Unaltered 
proliferation in (B, C, D, E) 4T1-BM2 CTGFkd 
cells (to 4T1-T2, NS, P=0.79, to 4T1-BM2, NS, 
P=0.52, students t test), in 4T1-BM2 IL1R2kd 
cells (to 4T1-T2, NS, P=0.72, to 4T1-BM2, NS, 
P=0.58, students t test), in 4T1-BM2 LAMC2kd 
cells (to 4T1-T2, NS, P=0.27, to 4T1-BM2, NS, 
P=0.78, students t test), in 4T1-BM2 EDN1kd 
cells (to 4T1-T2, NS, P=0.90, to 4T1-BM2, NS, 
P=0.48, students t test). Unaltered proliferation rate from 4T1-T2 parental compared to 4T1-
BM2 cells (NS, P=	  0.41, students t test). All values represent mean ± SEM. 
 
 
5.2. – The 4T1-BM2 Cx31kd cell line have reduced survival under hypoxic conditions.  
To determine the impact on 4T1-BM2 survival under hypoxia of one of the selected genes, 
we compared the growth of parental 4T1 and 4T1-BM2 cells as well as the silenced 4T1-
BM2 lines under hypoxic vs. normoxic conditions.  
Considering the number of cells and using the normalization of the data by calculating the 
hypoxia-normoxia ratio (Figure 2-3), the cell lines 4T1-BM2 Cx31kd, 4T1-BM2 EDN1kd 
showed a 49.4% and 12.1% decreased in survival, respectively, compared to the 4T1-BM2 
cell line at 24 hours. In addition, the 4T1-BM2 Cx31kd presents a decreased survival rate 
relative to the paternal cell line by 11.2% at 24 hours.  
The numerous cell lines used made it difficult to quantify the assays. In order to ease the 
effort, we reduced the number of lines tested at once. We added all four wells along a cell 
line and counted them. Nevertheless, there is the need to perform additional assays to 
perform statistical analysis of the results. 
 
Figure 2. Cell survival under hypoxia vs normoxia. 
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Figure 3. Relative cell survival under hypoxia vs normoxia. 
 
 
5.3. – 4T1-BM2 CTGFkd and 4T1-BM2 EDN1kd cell lines show a collective pattern of 
migration and reduced velocity compared to controls and other gene-silenced cell 
lines.  
To investigate the potential involvement of the selected genes in the migration process, we 
monitored the migration of the 4T1-T2, 4T1-BM2, 4T1-BM2 NS, 4T1-BM2 CTGFkd, 4T1-BM2 
Cx31kd and 4T1-BM2 EDN1kd cell lines during 24 hours. Microscopic analysis revealed a 
collective migration behavior of the 4T1-BM2 CTGFkd	   and 4T1-BM2 Cx31kd cell lines, 
particularly of the former (Figure 4). Conversely, a rather individual cell migration pattern 
was observed in other cell lines (Figure 5). The quantification of the migration velocity (µm / 
sec) revealed a clearly reduced speed of migration of the 4T1-BM2 CTGFkd and 4T1-BM2 
EDN1kd cell lines, whereas the 4T1-BM2, 4T1-BM2 NS and 4T1-BM2 Cx31kd cell lines has 
equal migration speed (Figure 6). 
 
 
Figure 4. 4T1-BM2 CTGFkd . Figure 5. 4T1-T2 
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Figure 6. Cell migration. Migration during 
24 hours of each cell line with the silenced 
genes, compared with the two control cell 
lines (4T1-T2 parental and 4T1-BM2 cells) 
is reduced in 4T1-BM2 CTGFkd cells (to 
4T1-T2, *, P<0.04, to 4T1-BM2, **, 
P<0.0085, students t test) and 4T1-BM2 
EDN1kd (to 4T1-T2, NS, P=0.076 to 4T1-
BM2, *, P<0.02, students t test), unaltered 
in 4T1-BM2 Cx31kd (to 4T1-T2, NS, 
P=0.53, to 4T1-BM2, NS, P=0.99, 
students t test). No difference in migration 
between 4T1-T2 parental and 4T1-BM2 
cells (NS, P=0.60, students t test). All 
values represent mean ± SEM. 
 
 
5.4. – Reduced capacity of 4T1-BM2 Cx31kd, 4T1-BM2 IL1R2kd and 4T1-BM2 EDN1kd to 
form mammospheres. 
To asses for stem cell self-renewal potential, we monitored for the capacity of the different 
lines to spontaneously assemble and grow as spheroids, using a mammosphere formation 
assay (Figure 7). We found a significant reduced number of spheroids formed by 4T1-BM2 
Cx31kd, 4T1-BM2 IL1R2kd and 4T1-BM2 EDN1kd lines compared to the 4T1-BM2 cell line by 
at least 18.4 ± 13.2 percent (p < 0.002). The 4T1-BM2 Cx31kd also presents a significant 
reduced number of formed spheroids compared to the paternal cell line 4T1-T2 by 26.1 ± 
17.1 percent (p < 0.001). In contrast, there were no significant differences in the number of 
formed spheroids by 4T1-BM2 CTGFkd and 4T1-BM2 LAMC2kd lines compared to the 4T1-
BM2 cell line (p > 0.1). Nevertheless, the 4T1-BM2 LAMC2kd cell line shows an increasing 
trend compared to all the other cell lines. According to experience, the parental 4T1-T2 cell 
line has a reduced ability to form spheroids compared with the 4T1-BM2 cell line (22.9 ± 8.4 
percent, p < 0.001).  
 
 
 
Figure 7. Mammosphere formation. Monitored spheroids formation of each cell line with 
the silenced genes, compared with the two control cell lines (4T1-T2 parental and 4T1-BM2 
cells) at 10 days is reduced in 4T1-BM2 Cx31kd cells (to 4T1-T2, ***, P<0.001, to 4T1-BM2, 
***, P<0.0001, students t test), 4T1-BM2 IL1R2kd (to 4T1-T2, NS, P=0.22, to 4T1-BM2, ***, 
P<0.0001, students t test) and 4T1-BM2 EDN1kd (to 4T1-T2, NS, P=0.33, to 4T1-BM2, **, 
P<0.002, students t test), unaltered in 4T1-BM2 CTGFkd cells (to 4T1-T2, NS, P=0.17, to 
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4T1-BM2, NS, P=0.11, students t test), in 4T1-BM2 LAMC2kd cells (to 4T1-T2, ***, P<0.0001, 
to 4T1-BM2, NS, P=0.09, students t test). Reduced spheroid formation from 4T1-T2 parental 
compared to 4T1-BM2 cells (***, P=0.0001, students t test). All values represent mean ± 
SEM. 
 
 
6 – Discussion 
The mechanisms governing breast cancer brain metastasis are largely unknown at the 
molecular level. Models to identify and study genes involved in this process have just been 
developed. A model of spontaneous breast cancer brain metastasis has been previously 
generated in the laboratory. Gene expression profile of 4T1 brain metastasis has been 
studied by microarray analysis. The aim of my work was to characterize the biological effects 
of some of the gene identified in these screens as associated with brain metastatic capacity. 
We expected to obtain results allowing us to point to the role of the targeted genes in 
promoting one of these activities potentially involved in metastasis formation. The results 
should allow us to demonstrate or dismiss a potential correlation between one or more of the 
selected genes and the aggressive, brain metastatic behavior of the 4T1-BM2 cells. 
 
We provide evidence that the Cx31 protein is relevant for the metastatic spread in breast 
cancer brain metastatic (4T1-BM2) cells. Increased Cx31 expression is a characteristic of 
4T1-BM2 cells. While a previous study has identified members of the connexin family to 
promote HeLa cell invasion (Ref. 6) our findings show for the first time that a knockdown 
proceeding on Cx31 in brain metastatic cells decreases the growth rate. In comparing the 
proliferation rate of the gene-silenced cells with parental tumor and brain metastatic cells, we 
have been able to demonstrate a reduced proliferative capacity of 4T1-BM2 Cx31kd 
compared to the 4T1-BM2 cells. But also the main difference from the parental cells is in 
particular to consider the role according to the growth capacity in general. This probably 
speaks for a reduced cell interaction with respect to growth-promoting factors and cell 
architecture. 
Furthermore, our finding that Cx31 knockdown is correlated to greatly reduced survival under 
hypoxic conditions, compared the growth of the cell lines under hypoxic vs. normoxic 
conditions during 24 hours, provides compelling evidence that disruption of intercellular 
communication by connexins in breast cancer brain metastatic cells has a particular 
importance on overcoming stress conditions. Incidentally, even the knockdown of EDN1 
peptide shows a reduced capacity for survival under hypoxia compared with the 4T1-BM2 
but not with the parental tumor cells. Also, the EDN1 expression is particularly increased in 
4T1-BM2 cells compared to the parental tumor cells. The involvement of auto- and paracrine 
growth factor activity (Ref. 8-9) in stress conditions is still open for discussion, but the 
presumption of the lack of increased growth factor secretion during hypoxia seems to prove 
as right. 
Our results from the wound closure assay show a collective pattern of migration and reduced 
speed of the 4T1-BM2 CTGFkd and 4T1-BM2 EDN1kd cell lines. Concerning CTGF, this 
results complement the observations from the Wang, Xie and Chen reports (Ref. 12-14) as to 
the link to increased tumor size and lymph node metastasis, as well as to resistance to 
apoptotic stress by having an important impact on migration speed and character. EDN1 is 
regarding the same complemented properties. 
Given the established role for the gene-silenced cell lines in proliferation, migration and 
resistance to hypoxia, it was important to demonstrate	   stem cell self-renewal potential of 
giving cell populations as well. We found greatly reduced capacity in 4T1-BM2 Cx31kd, and 
slightly in 4T1-BM2 IL1R2kd and 4T1-BM2 EDN1kd to form mammospheres. Again, we found 
a large deficit in the Cx31 gene knock down compared to the two controls suggesting, that 
the absence of Cx31 decreases the capacity to form spheroids. The EDN1 peptide silencing 
shows only a models reduction of spheroid formation in comparison to 4T1-BM2 cells. With 
regard to IL1R2 the difference achieved in the ability to form spheroids is almost 30 percent 
lower than the 4T1-BM2 cells. This finding supports the report by Matsuo et al’s (Ref. 22), 
proposing that the microenvironment might benefit from the angiogenic and proliferative 
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properties of IL1 secreted by pancreatic cancer cells. Consistent with this hypothesis, IL1R2 
is overexpressed in 4T1-BM2 cells and findings of several studies regarding breast cancer 
cells in the past shown that IL-1 alpha enhances the invasiveness of tumor cells (Ref. 23-25), 
as well as IL-1 beta, including tumor-induced angiogenesis and immunosuppression (Ref. 
26). 
 
The obtained results suggest a possibly important role of Cx31 in brain metastasis, although 
EDN1, CTGF, as well as IL1R2 consistent with metastasis promotion, the next step would be 
to test their function in mice in vivo (i.e. to test the effect of gene silencing on brain 
metastasis formation). While this part of the work will be out of the scope of my Master 
thesis, it will be a necessary step toward the further understanding of the mechanisms of 
brain cancer metastasis. This will be essential, especially in order to confirm our findings 
from recent study reporting reduced cell proliferation, inhibited anchorage-independent 
growth and suppressed cell migration and invasion, in the non-small cell lung cancer 
(NSCLC) –derived cell line H1299 cells overexpressing Cx31.1 (Ref. 27). 
 
In conclusion, though the in vitro functional characterization of proliferation, migration, 
survival in hypoxia and mammosphere formation, five different genes of interest selected for 
their potential clinical relevance for brain metastasis formation, we demonstrate that the 
Cx31 protein promotes cell proliferation, survival under hypoxia and stem cell self-renewal 
potential. These findings are consistent with a prometastatic role of Cx31. Our study also 
provides evidence for a pro-migratory, anti-apoptotic and stem cell self-renewal potential for 
the EDN1 peptide. CTGF seems also to promote migration, and IL1R2 to promote stem cell 
self-renewal potential.  
 
Metastasis formation and lack of effective therapeutic options are the main causes of cancer 
patient’s death, in contrast to localized cancers, which can be effectively treated by surgery. 
The Identification of genes mediating breast cancer metastasis in general (e.g. to bones, 
lung, liver) and to brain in particular is highly relevant to the understanding of the biology of 
breast cancer metastasis formation and might open novel therapeutic options to their 
prevention and treatment in patients (Ref. 28). 
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